CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
GLIOMATCH aims to enhance treatment outcomes for patients with malignant gliomas by integrating immunology and imaging data. It focuses on personalized therapy matching through advanced tissue mapping and machine learning to improve patient stratification and treatment follow-up.
Adult and paediatric malignant glioma (GBM and pHGG) remain among the most difficult-to-treat cancers with 5-year survival rates of <5% despite intensive standard-of-care therapy.
The differences among patients and the heterogeneous and plastic nature of each individual tumour have resulted in all therapeutic clinical trials failing during the past 20 years.
Recently, immunotherapy has been showing great promise, but only in subsets of patients.
Identifying those patients cannot be done a priori…
KATHOLIEKE UNIVERSITEIT LEUVEN
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Netherlands, Rotterdam
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Netherlands, Maastricht
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Norway, Oslo
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Spain, Esplugues De Llobregat
Type: Research institute
Activity type: Research Organisations
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
Guests see up to 5 keywords.
